Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00045
[1]
RNA modification MYC MYC TRMT10A Methylation : modification sites Direct Enhancement m6A modification MYC MYC FTO Demethylation : m6A sites
m6A Modification:
m6A Regulator Fat mass and obesity-associated protein (FTO) ERASER
m6A Target Myc proto-oncogene protein (MYC)
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> N1-methylguanosine (m1G)
Epigenetic Regulator tRNA methyltransferase 10 homolog A (TRMT10A) WRITER View Details
Regulated Target Myc proto-oncogene protein (MYC) View Details
Crosstalk Relationship m1G  →  m6A Enhancement
Crosstalk Mechanism RNA modification directly impacts m6A modification through recruiting m6A regulator and targeting the shared RNA
Crosstalk Summary TRMT10A may enhance FTO's demethylation activity and selectivity on m6A sites in poly(A)-RNA (Myc proto-oncogene protein (MYC); FOXD1; AUPKAIP1; ATP7A and ERCC5).
Responsed Drug AVI-5126
Pathway Response RNA degradation hsa03018
Cell Process mRNA decay
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Myc proto-oncogene protein (MYC) 3 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name AVI-5126 Phase 2 [2]
Synonyms
Resten-CP; NeuGene (CABG), AVI
    Click to Show/Hide
External Link
 Compound Name Resten-NG Phase 2 [3]
Synonyms
Resten-NG (TN)
    Click to Show/Hide
External Link
 Compound Name TWS-119 Investigative [4]
Synonyms
TWS119; 601514-19-6; 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol; TWS 119; GSK inhibitor XII; GSK-3beta Inhibitor XII, TWS119; Neurogenesis Inducer, TWS119; CHEMBL405759; 3-(6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenol; 3-((6-(3-AMINOPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)OXY)PHENOL; 3-{[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy}phenol; Phenol, 3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-; K00245; MLS006011018; GTPL5980; SCHEMBL5559045; GSK-3BETA INHIB
    Click to Show/Hide
External Link
References
Ref 1 Coordination of mRNA and tRNA methylations by TRMT10A. Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):7782-7791. doi: 10.1073/pnas.1913448117. Epub 2020 Mar 25.
Ref 2 Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J Ocul Pharmacol Ther. 2012 Apr;28(2):194-201. doi: 10.1089/jop.2011.0135. Epub 2011 Dec 7.
Ref 3 Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56. doi: 10.1002/ccd.1277.
Ref 4 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.